Janus kinase 1 inhibitor abrocitinib for isolated nail lichen planus: a case report and literature review
Aim This study aims to evaluate the efficacy and safety of the Janus kinase 1 (JAK1) inhibitor abrocitinib for treating nail lichen planus (NLP) and to review available case reports documented in English.Methods We reported the first case of a patient with isolated NLP treated with the selective JAK...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2434094 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Aim This study aims to evaluate the efficacy and safety of the Janus kinase 1 (JAK1) inhibitor abrocitinib for treating nail lichen planus (NLP) and to review available case reports documented in English.Methods We reported the first case of a patient with isolated NLP treated with the selective JAK1 inhibitor abrocitinib. The patient received 100 mg of oral abrocitinib daily.Results After 6 months, the patients showed 82.35% improvements in the Dermatology Life Quality Index (DLQI) and 79.17% improvement in the Nail lichen planus severity index (tNLPSI), which were consistent with the clinical improvement, correlating with clinical improvement. In the subsequent 6 months, the dose was reduced to 100 mg every other day, with further improvement in onycholysis.Conclusions This case suggests that abrocitinib can be both safe and effective for treating NLP. |
|---|---|
| ISSN: | 0954-6634 1471-1753 |